Novartis forms alliance to develop medicines for treating infectious diarrheal disease

NovartisNovartis and the Bill & Melinda Gates Foundation have formed an alliance to advance development of Novartis' drug candidate KDU731 for the treatment of cryptosporidiosis. Diarrheal diseases are one of the leading causes of childhood mortality globally, resulting in approximately 525,000 deaths each year and cryptosporidiosis is the second leading cause of infectious diarrhea in children under 2 years of age[1]-[2]. "There is an urgent medical need for new and effective therapeutics for cryptosporidiosis, particularly in vulnerable populations" said Dr. Paul Kelly University of Zambia School of Medicine and Tropical Gastroenterology at Barts & The London.

KDU731 is a Cryptosporidium lipid kinase PI(4)K (phosphatidylinositol-4-OH kinase) inhibitor, which has been shown to effectively treat Cryptosporidium infection in preclinical models[3] and is currently undergoing safety studies prior to the initiation of clinical trials. Under the terms of the agreement, the Bill & Melinda Gates Foundation will provide $6.5 million to support the development of this drug candidate for the treatment of children by the Novartis Institute for Tropical Diseases (NITD).

"We are committed to the fight against cryptosporidiosis and other infectious and neglected tropical diseases and are proud to work closely with the Bill & Melinda Gates Foundation and other partners in this effort," said Thierry Diagana, Head of NITD. "Today's global health issues cannot be solved by one organization alone. Private companies, governments, non-governmental organizations, academia, and other stakeholders need to work together to create sustainable solutions."

NITD is a Novartis research institute dedicated solely to the discovery and development of new medicines to treat malaria, cryptosporidiosis, and three major kinetoplastid diseases - human African trypanosomiasis (sleeping sickness), chagas disease and leishmaniasis.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

1. http://www.who.int/mediacentre/factsheets/fs330/en/
2. Kotloff, KL et al., "Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multisite Study, GEMS): a prospective, case-control Study." Lancet 2013 Jul 20; 382 (9888): 209-22
3. Manjunatha, UH et al., "A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis" Nature 2017 June 14; 546 (7658): 376-80

Most Popular Now

Pfizer begins a Phase 1/2 study to evaluate respir…

Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV i...

Eczema drug effective against severe asthma

Two new studies of patients with difficult-to-control asthma show that the eczema drug dupilumab alleviates asthma symptoms and improves patients' ability to breathe bett...

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

Novartis data at ASCO and EHA reinforce company's …

Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 ...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study demonstrates new treatment for severe asthma

Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, together with colleagues at other partnering ...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...